CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension The HACD4 haplotype as a risk factor for atherosclerosis in males Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America Astro-CHARM, the First 10-year ASCVD Risk Estimator Incorporating Coronary Calcium Ticagrelor or Prasugrel in Patients with ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) Comparison of Stenting Versus Bypass Surgery According to the Completeness of Revascularization in Severe Coronary Artery Disease: Patient-Level Pooled Analysis of the SYNTAX, PRECOMBAT, and BEST Trials Syncope After Percutaneous Coronary Intervention

Clinical Trial 2001 Jan 2;103(1):10-3.

JOURNAL:Circulation. Article Link

Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension

Feinstein JA, Goldhaber SZ, Lock JE et al. Keywords: Balloon pulmonary angioplasty; chronic thromboembolic pulmonary hypertension

Abstract


BACKGROUND - Although pulmonary thromboendarterectomy is increasingly successful for the definitive treatment of chronicthromboembolic pulmonary hypertension (CTEPH), not all patients have surgically accessible disease. Others are poor surgical candidates because of comorbid illness. Therefore, for selected patients, we defined and implemented an alternative interventional strategy of balloon pulmonary angioplasty (BPA).

METHODS AND RESULTS - Eighteen patients (mean age, 51.8 years; range, 14 to 75 years) with CTEPH underwent BPA; they averaged 2.6 procedures (range, 1 to 5) and 6 dilations (range, 1 to 12). Selection of pulmonary artery segments for dilation required (1) complete occlusion, (2) filling defects, or (3) signs of intravascular webs. After an average of 36 months of follow-up (range, 0.5 to 66 months), the average New York Heart Association class improved from 3.3 to 1.8 (P:<0.001), and 6-minute walking distances increased from 209 to 497 yards (P:<0.0001). Pulmonary artery mean pressures decreased from 43.0+/-12.1 to 33. 7+/-10.2 mm Hg (P:=0.007). Eleven patients developed reperfusion pulmonary edema; 3 required mechanical ventilation.

CONCLUSIONS - BPA reduces pulmonary artery hypertension in patients with CTEPH and is associated with long-term improvement in New York Heart Association class and 6-minute walking distances. BPA is a promising interventional technique that warrants randomized comparison with medical therapy in CTEPH patients who are not surgical candidates.